ABL1 and leukemia: Increased DSBs and reduced clonogenic potential of imatinib-refractory CML cell lines and primary samples, including under hypoxic conditions mimicking the bone marrow microenvironment. Eliminated quiescent cells in an inducible mouse model of chronic-phase CML. Reduced leukemic burden up to 10-fold in a BCR-ABL1+ leukemia xenograft model.